Please login to the form below

Not currently logged in

Tudor Reilly to provide the Alkaptonuria Society with free consultancy support

The patient group is looking to fund drug trials for the rare genetic condition

Healthcare agency Tudor Reilly has agreed to provide £10,000 worth of consultancy support pro bono to the patient group Alkaptonuria (AKU) Society.

The agency's support will assist the patient group as it works towards ensuring that the drug nitisinone is tested in a Phase III trial.

The genetic enzyme deficiency disease can lead to the breakdown of cartilage, which becomes black and brittle and typically results in joint pain and the early-onset of osteoarthritis.

"As a strategic healthcare communication specialist, we understand the enormous achievements of the AKU Society in developing advocacy, fundraising and formulating a ground-breaking strategy in order to find a cure," said Julie Walters, managing director of Tudor Reilly.

"We are proud to support Nick Sireau and his team and look forward to being involved in his future success."

Over the last 10 years, the Liverpool-based society has established a multidisciplinary network, including representatives from 12 universities and hospitals, seven pharmaceutical companies and four national AKU patient groups in Europe and North America. While also funding two research programmes into AKU and the first AKU information centre.

"Normally, clinical trials are designed and developed by pharmaceutical companies as it's a complicated and expensive business," said Nick Sireau, AKU Society Chairman, whose two young sons suffer from the rare genetic condition. "But when dealing with rare diseases, patients can be proactive and take control of their own future."

21st August 2012


Featured jobs

Subscribe to our email news alerts


Add my company

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...